Cargando…

Correction: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279654/ https://www.ncbi.nlm.nih.gov/pubmed/32345628 http://dx.doi.org/10.1136/jitc-2020-0737-3corr1

Ejemplares similares

Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
por: Wu, Hao-Xiang, et al.
Publicado: (2019)

Correction: Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
Publicado: (2023)

Correction: Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
por: Kim, Min Hwan, et al.
Publicado: (2020)

Correction to: Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade
por: Natoli, Marina, et al.
Publicado: (2020)

Correction: Gallic acid induces T-helper-1-like Treg cells and strengthens immune checkpoint blockade efficacy
Publicado: (2022)

Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer
por: Wang, Yujiao, et al.
Publicado: (2022)

Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
por: Hama, Naoki, et al.
Publicado: (2022)

TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma
por: Qiu, Tianzhu, et al.
Publicado: (2022)

Predictive biomarkers for tumor immune checkpoint blockade
por: Tong, Mengting, et al.
Publicado: (2018)

Microbial biomarkers for immune checkpoint blockade therapy against cancer
por: Adachi, Keishi, et al.
Publicado: (2018)

Immune checkpoint alterations and their blockade in COVID-19 patients
por: Tan, Jiaxiong, et al.
Publicado: (2022)

Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
por: Gao, Mei, et al.
Publicado: (2020)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
por: Peranzoni, Elisa, et al.
Publicado: (2020)

Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
por: Xiao, Qingyang, et al.
Publicado: (2020)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
por: Lei, Yanna, et al.
Publicado: (2021)

Correction: Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
Publicado: (2023)

Correction: TET2 deficiency promotes MDS-associated leukemogenesis
por: Huang, Feiteng, et al.
Publicado: (2023)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020)

MTHFR act as a potential cancer biomarker in immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration
por: Peng, Jianheng, et al.
Publicado: (2023)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
por: Shen, Hongxing, et al.
Publicado: (2019)

A Comprehensive Benchmark of Transcriptomic Biomarkers for Immune Checkpoint Blockades
por: Kang, Hongen, et al.
Publicado: (2023)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Correction: Immune checkpoint inhibitor-associated celiac disease
Publicado: (2020)

Correction: T lymphocyte-targeted immune checkpoint modulation in glioma
Publicado: (2020)

Correction: Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
por: Sun, Shangqin, et al.
Publicado: (2021)

The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
por: Xu, Yufei, et al.
Publicado: (2022)

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
por: Pabla, Sarabjot, et al.
Publicado: (2019)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Correction to: Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
por: Rose, Tracy L., et al.
Publicado: (2022)

Gastric Cancer in the Era of Immune Checkpoint Blockade
por: Figueroa-Protti, Lucía, et al.
Publicado: (2019)

Correction: On the mechanism of anti-CD39 immune checkpoint therapy
Publicado: (2020)

Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2020)

Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers
por: Zhong, Jie, et al.
Publicado: (2023)

Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Publicado: (2021)

Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Publicado: (2022)

Publisher Correction: TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential
por: He, Jing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_efvvpkrmo7n7jp8qkr1va348km